Status:

UNKNOWN

Androcur® (Cyproterone Acetate) and Meningioma Development: a Genotype-environment Association Study

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Conditions:

Meningioma

Eligibility:

FEMALE

18+ years

Brief Summary

The primary objective of the study is to create a biobank of oral smears permitting to identify the genetic locus/loci associated with an increased risk to develop meningiomas after cyproterone acetat...

Detailed Description

The increased risk to develop a meningioma has recently been established for patients received the cyproterone acetate. The investigators observed several familial cases of CPA related meningiomas wh...

Eligibility Criteria

Inclusion

  • Age ⩾18 years;
  • Non-opposition opinion obtained during the first phone call at the beginning of the study;
  • Covered by the french social security scheme.
  • For the group 1:
  • Meningioma diagnosed by medical imaging and confirmed histologically if surgery occurred;
  • Cyproterone acetate taken for at least 6 months, 25 mg par day and 20 day by month (cumulated dose ⩾ 3 000mg).
  • For the group 2:
  • Cyproterone acetate taken for at least 5 years with dose of 50 mg per day and 20 day by month, or a cumulated dose corresponding to a longer period (⩾ 30 000mg);
  • Normal result of RMI examination performed after at least 5 years treatment by cyproterone acetate.
  • For the group 3 :
  • Subject who has never taken cyproterone acetate;
  • Meningioma diagnosed by medical imaging examination and confirmed histologically if surgery occured.
  • For the group 4 :
  • Subject who has never taken cyproterone acetate;
  • Subject never diagnosed with meningioma.

Exclusion

  • Subject under tutoraship;
  • Subject refusal;
  • Communication difficulties such as: language barriers, serious problems of hearing without a hearing instrument, cognitive troubles... ;
  • Foreign subject under AME scheme (a french social system).

Key Trial Info

Start Date :

July 6 2021

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

April 19 2025

Estimated Enrollment :

2000 Patients enrolled

Trial Details

Trial ID

NCT04372095

Start Date

July 6 2021

End Date

April 19 2025

Last Update

October 30 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Endocrinology Nutrition Department, Ambroise Paré Hospital, APHP

Boulogne-Billancourt, France, 92100